

## April 21, 2023 | Issue 268

#### Editor's note

This note is produced every Friday by the <u>KPMG Center for Healthcare</u> <u>Regulatory Insight</u> and is intended to be short and succinct, no more than 360 words, to provide a digestible bite of healthcare and life sciences news from the past week. Please share this email with colleagues and other interested individuals, and encourage them to <u>subscribe to our mailing list here</u>.

We welcome your feedback. Let us know if KPMG can help. Please <u>reply</u> <u>here to me</u>, **Larry Kocot**, principal and national leader, KPMG Center for Healthcare Regulatory Insight or simply reply to this email with any comments or requests.





# Healthcare regulatory news

President Biden <u>signed an Executive Order</u> to, among other things, increase access to childcare and long-term care.

The 2024 ACA Marketplace final rule phases in a limit on non-standardized plans, creates a SEP for eligible individuals losing Medicaid/CHIP coverage, and includes new essential community provider categories for substance use disorder and mental health facilities.

CMS <u>released ownership information</u> for all Medicare-certified <u>hospice</u> and home <u>health</u> agencies.

HHS will offer free online cybersecurity training for healthcare workers.

HHS <u>released guidance encouraging states</u> to apply for a Medicaid demonstration to <u>increase healthcare for individuals leaving carceral</u> facilities.

-



### Healthcare law and policy news

The Supreme Court <u>extended the hold</u> on restrictions to mifepristone until midnight tonight.

President Biden is <u>expected to nominate National Cancer Institute Director</u>, <u>Monica Bertagnolli</u>, as NIH Director.

Merck will acquire Prometheus Biosciences (\$10.8B)... GlaxoSmithKline will acquire Bellus (\$2B)... Epic expanded collaboration with Microsoft to integrate AI technology into its EHR software... Kaufman Hall reported health system M&A transaction value was \$12.4B in Q1 2023, up from \$3B in Q1 2022, with increasing transactions between midsized regional systems.

Mark Cuban Cost Plus Drug Company <u>created a network of 36 pharmacies</u> to <u>accept a prescription drug discount card</u>... Express Scripts announced <u>an initiative to increase reimbursement for independent rural pharmacies</u>.

Emergent BioSolutions <u>plans to charge "less than \$50"</u> for a two-pack of over-the-counter naloxone.

ICER <u>concluded</u> Eisai-Biogen's Alzheimer's drug lecanemab <u>does not show a net health benefit over current treatment options</u> and represents "low" long-term value at current cost... A <u>JAMA study found 27 of 50 top-selling Medicare drugs</u> had a "low added therapeutic benefit" rating from European health technology assessment organizations.

Turquoise Health reported <u>84% of hospitals have posted machine-readable pricing data files</u>, up from <u>76% in Q3 2022</u>... A <u>Health Affairs study</u> found hospital cash prices were lower than median commercial negotiated rates in 47% of instances examined... A <u>National Council of State Boards of Nursing survey</u> found <u>nearly 100,00 registered nurses left the field during the pandemic</u> and nearly one-fifth of RNs (900,000 more) could leave by 2027... Health Care Cost Institute <u>reported healthcare spending for individuals</u> with employer-sponsored insurance increased 15% in 2021 and 21.2% cumulatively from 2017 to 2021.

-



FDA (1) <u>authorized a bivalent-only COVID-19 vaccine regimen</u> for individuals ages 6 months and older and declared that Pfizer-BioNTech's and Moderna's two-dose monovalent COVID-19 vaccine regimens are no longer authorized for use; and (2) authorized a second omicron-targeted bivalent COVID-19 vaccine for individuals 65 and older or who are immunocompromised... CDC's vaccine advisory <u>committee broadly</u> supported, and the CDC <u>Director recommended</u>, the changes.

The Biden Administration <u>announced a \$1.1B program</u> to cover COVID-19 vaccines for unvaccinated individuals through 2024.

HHS <u>announced amendments to the PREP Act emergency declaration</u>, including permitting pharmacists, pharmacy technicians, and pharmacy interns to continue administering COVID-19 vaccines and test and influenza vaccines through December 2024.

AstraZeneca reported its <u>antibody treatment appeared effective at</u> <u>neutralizing all known COVID-19 variants</u> in immunocompromised patients and that it could be available by the end of the year.

A group of infectious disease doctors and epidemiologists <u>proposed</u> <u>dropping universal mask requirements</u> in healthcare settings.

A <u>STAT-Harris Poll survey found</u> 46% of Americans are familiar with RSV, and of those familiar, 71% are concerned their children may contract RSV and 57% are concerned their older parents or relatives may get sick.

-



Questions or comments, please send to <u>us-hclspractice@kpmg.com</u>.

### kpmg.com/socialmedia











Privacy | Legal

You have received this message from KPMG LLP. If you wish to unsubscribe from Around the world of U.S. healthcare in 360 words or less, please  $\underline{\text{click here}}$ . If you wish to unsubscribe from all KPMG communications, please  $\underline{\text{click here}}$ .

KPMG LLP, 3 Chestnut Ridge Road, Montvale, NJ 07645

© 2023 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. NDP295619-1E

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.